KROS - Keros Therapeutics Inc
Keros Therapeutics Inc Logo

KROS - Keros Therapeutics Inc

https://www.kerostx.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a great unmet medical need. The company is headquartered in Lexington, Massachusetts.

52W High
$72.37
52W Low
$9.12
MA Status:
50D: Above 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.07
Valuation
Fair
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
48.72
Forward P/E (<15 better)
15.65
EV/EBITDA (<8 favorable)
-13.05
EV/Revenue (<3 favorable)
6490.26
P/S (TTM) (<3 favorable)
2.72
P/B (<3 favorable)
0.90
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
2.73%
Institutions (25–75% balanced)
100.64%
Shares Outstanding
40,615,400
Float
28,055,500
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
232,844,000
Gross Profit (TTM)
219,405,000
EPS (TTM)
0.32
Profit Margin (>10% good)
0.08%
Operating Margin (TTM) (higher better)
-2.19%
ROE (TTM) (>15% strong)
0.03%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
490.03
Momentum
Bearish momentum
Value
0.4219
Previous
0.4394
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025